[18F]FDG PET/CT Imaging and Hematological Parameters Can Help Predict HPV Status in Head and Neck Cancer
To determine whether [<sup>18</sup>F]FDG PET/CT and hematological parameters provide supportive data to determine HPV status in HNSCC patients.Retrospective analysis of clinical and diagnostic data from 106 patients with HNSCC: 26.4% HPV-positive and 73.6% HPV-negative was performed. The following semiquantitative PET/CT parameters for the primary tumor and hottest lymph node and liver were evaluated: SUV<sub>max</sub>, SUV<sub>mean</sub>, TotalSUV, MTV, TLG, maximum, mean and TLG tumor-to-liver ratio (TLR<sub>max</sub>, TLR<sub>mean</sub>,TLR<sub>TLG</sub>) and heterogeneity index (HI). Following hematological variables were assessed: white blood cell (WBC); lymphocyte (LYMPH); neutrophil (NEU),monocyte (MON); platelet (PLT); neutrophil-to-lymphocyte ratio (NRL); lymphocyte-to-monocyte ratio (LMR); platelet-to lymphocyte ratio (PLR) and monocyte-to-lymphocyte ratio (MLR). Conventional statistical analyses were performed in parallel with an artificial neural network analysis (Neural Analyzer, v. 2.9.5).Significant between-group differences were observed for two of the semiquantitative PET/CT parameters, with higher values in the HPV-negative group: primary tumor MTV (22.2 vs 9.65; p=0.023), and TLR<sub>max</sub> (3.50 vs 2.46; p=0.05). The HPV-negative group also had a significantly higher NEU count (4.84 vs. 6.04; p=0.04), NEU% (58.2 vs. 66.2; p=0.007), and NRL% (2.69 vs. 3.94; p=0.038). Based on ROC analysis (sensitivity 50%, specificity 80%, AUC 0.5), the following variables were independent predictors of HPV-negativity: primary tumor with SUV<sub>max</sub> >10; TotalSUV >2800; MTV >23.5; TLG >180; TLR<sub>max</sub> >3.7; TLR<sub>TLG</sub> >5.7; and oropharyngeal localization.Several semiquantitative parameters derived from [<sup>18</sup>F]FDG PET/CT imaging of the primary tumor (SUV<sub>max</sub>, TotalSUV, MTV, TLG, TLR<sub>max</sub> and TLR<sub>TLG</sub>) were independent predictors of HPV-negativity.
Authors
- Joanna Kaźmierska (ORCID: https://orcid.org/0000-0001-7160-8150)
- Krzysztof Matuszewski (ORCID: https://orcid.org/0000-0002-9119-8985)
- Geoffrey Michael Currie (ORCID: https://orcid.org/0000-0002-6180-8586)
- Paweł Golusiński (ORCID: https://orcid.org/0000-0002-3937-5315)
- Joanna Wróblewska (ORCID: https://orcid.org/0000-0002-0544-321X)
- Andrzej Marszałek (ORCID: https://orcid.org/0000-0002-6055-9151)
- Paulina Cegła (ORCID: https://orcid.org/0000-0002-6676-3436)
- Witold Cholewiński
- Wojciech Golusiński (ORCID: https://orcid.org/0000-0002-6075-3464)
- Inga Jagiełło (ORCID: https://orcid.org/0009-0009-1109-2303)
- Ewa Majchrzak (ORCID: https://orcid.org/0000-0003-3555-2318)
- Anna Kubiak (ORCID: https://orcid.org/0000-0001-7363-5654)
Institutions
- Poznan University of Medical Sciences (PL)
- Charles Sturt University (AU)
- Greater Poland Cancer Center (PL)
- University of Zielona Góra (PL)
Publication Details
- Journal
- Nuklearmedizin - NuclearMedicine
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1055/a-2365-7808
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00